Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009143 | 0.95 | CRBN (0.49) | CRBNDDB1USP30GPR119EPHX2 | |
| SCHEMBL23123218 | 0.95 | CRBN (0.49) | CRBNDDB1USP30GPR119EPHX2 | |
| SCHEMBL23134050 | 0.88 | CRBN (0.42) | CRBNDDB1USP30GPR119EPHX2 | |
| SCHEMBL23173797 | 0.87 | CRBN (0.56) | CRBNDDB1USP30GPR119EPHX2 | |
| SCHEMBL28783614 | 0.84 | DDB1 (0.47) | CRBNDDB1KDM4E | |
| SCHEMBL30392744 | 0.83 | CRBN (0.51) | CRBNDDB1USP30EPHX2 | |
| SCHEMBL23121669 | 0.83 | DDB1 (0.46) | CRBNDDB1 | |
| SCHEMBL23134742 | 0.83 | DDB1 (0.44) | CRBNDDB1 | |
| SCHEMBL23133973 | 0.83 | DDB1 (0.44) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL23122759 | 0.82 | DDB1 (0.46) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | CRBN 1543/4885DDB1 200/4885USP30 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.